Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arthrocare ReFlex Wand Helps Whip Up 39% Stock Gain In July

This article was originally published in The Gray Sheet

Executive Summary

Introduction of the ReFlex surgical wand helped conjure up a 39% increase in Arthrocare stock in July. The issue gained 8 points to close the month at 28-1/2.

You may also be interested in...



Inamed To Finalize $142 Mil. Collagen Aesthetics Acquisition By Oct. 1

Inamed is looking to build a $225 mil. global plastic and aesthetic surgery device business through the acquisition of Palo Alto, California-based Collagen Aesthetics.

Summit Excimer Laser Approvable For LASIK Up To -14 D Myopia, Panel Says

Summit Technologies' SVS Apex Plus excimer laser workstation with emphasis discs is approvable with conditions for the correction of myopia up to -14 diopters with or without astigmatism ranging from -0.5 to -5 D, FDA's Ophthalmic Devices Panel concluded at its July 23 meeting.

Visx' Star S2 Excimer Laser Approvable For LASIK With Conditions - Panel

A July 22 recommendation that Visx' Star S2 excimer laser be approved for in situ keratomileusis (LASIK) procedures was precipitated by a consensus desire on the part of FDA's Ophthalmic Devices Panel to disseminate study data through product labeling.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel